Table 2.
Baseline characteristics and treatment effect of patients considering each pretreatment imaging modality (duplication was allowed)
| CT (including simulation CT) (n = 131) |
MRI (n = 54) |
Bone scintigraphy (n = 56) |
18FDG-PET (n = 14) |
|
|---|---|---|---|---|
| Age, years; median (range) | 66 (24–89) | 67 (35–89) | 67 (24–89) | 66 (48–84) |
| Sex | ||||
| Male | 78 (60%) | 34 (63%) | 33 (59%) | 8 (57%) |
| Female | 53 (40%) | 20 (37%) | 23 (41%) | 6 (43%) |
| Primary site | ||||
| Lungs | 35 (27%) | 14 (26%) | 25 (45%) | 4 (29%) |
| Genitourinary tract | 34 (26%) | 16 (30%) | 10 (18%) | 6 (43%) |
| Gastrointestinal tract | 34 (26%) | 14 (26%) | 14 (25%) | 1 (7%) |
| Breasts | 6 (5%) | 3 (6%) | 2 (4%) | 0 (0%) |
| Head and neck | 5 (4%) | 3 (6%) | 1 (2%) | 2 (14%) |
| Thyroid | 4 (3%) | 1 (2%) | 1 (2%) | 0 (0%) |
| Gynecology | 4 (3%) | 0 (0%) | 0 (0% | 0 (0%) |
| Unknown | 9 (7%) | 3 (6%) | 3 (5%) | 1 (7%) |
| Histology | ||||
| Squamous cell carcinoma | 9 (7%) | 5 (9%) | 4 (7%) | 2 (14%) |
| Adenocarcinoma | 66 (50%) | 25 (46%) | 28 (50%) | 6 (43%) |
| Small cell carcinoma | 4 (3%) | 3 (6%) | 4 (7%) | 0 (0%) |
| Clear cell carcinoma | 22 (17%) | 9 (17%) | 11 (20% | 1 (7%) |
| Others | 27 (21%) | 10 (19%) | 7 (13%) | 5 (36%) |
| Unknown | 3 (2%) | 2 (4%) | 2 (4%) | 0 (0%) |
| Metastatic site | ||||
| Vertebral | 86 (66%) | 44 (81%) | 38 (68%) | 8 (57%) |
| Non-vertebral | 45 (34%) | 10 (19%) | 18 (32%) | 6 (43%) |
| Bone metastases type | ||||
| Osteolytic | 88 (67%) | 43 (80%) | 39 (70%) | 9 (64%) |
| Osteoblastic | 34 (26%) | 7 (13%) | 13 (23%) | 4 (29%) |
| Mixed | 9 (7%) | 4 (7%) | 4 (7%) | 1 (7%) |
| Pathological fracture | ||||
| Present | 24 (18%) | 9 (17%) | 9 (16%) | 4 (29%) |
| Absent | 107 (82%) | 45 (83%) | 47 (84%) | 10 (71%) |
| Treatment effect | ||||
| Response | 105 (80%) | 43 (80%) | 45 (80%) | 12 (86%) |
| Non-response | 26 (20%) | 11 (20%) | 11 (20%) | 2 (14%) |
CT computed tomography, MRI magnetic resonance imaging, 18FDG-PET 18fluorodeoxyglucose-positron emission tomography